Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Please go ahead. Thank you and good morning. Our press release for the company's second quarter 2025 financial results and business updates became available at 7 a.m. Eastern time this morning and can be found on the Investors in Use section of the company's website. The company has also posted an updated corporate presentation to the website. I'd like to remind you that we're making forward-looking statements including statements about the timing and results of our clinical studies and data readouts, future product candidates, clinical development plans and commercial opportunities, communications with feedback from or submissions to the FDA, operating plans and our future cash runway, future obligations related to the vows sale, our ability to secure a business development deal, partnerships and or generate or obtain additional capital or financing, our planned strategic focus, anticipated timing of any of the foregoing and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the risk factor section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future but we disclaim any obligation to do so. On today's call with prepared remarks, I'm joined by Morela Thorell, co-CEO and CFO and Matthew Penn, Chief Scientific Officer. Additional members of the management team including Tom DeRosier, co-CEO and Chief Legal Officer, Terry Young, Chief Commercial and Strategy Officer and Dennis Walley, MD, Senior Vice President of Clinical Development will also be available during the Q&A portion of the call. And with that, I'll pass the call o...